XOMA Royalty Corp. (XOMA) Stock Score, Valuation & Financial Research
XOMA Royalty Corp. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 51/100.
Quick answer for XOMA
XOMA Royalty Corp. currently has a Wall Street Score of 51/100. The stored market price is $40.17. Its financial score is 60/100. Its valuation score is 72/100. These figures are a research snapshot, not a buy or sell recommendation.
What XOMA Royalty Corp. does
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main o
XOMA financial snapshot
- Wall Street Score:
- 51/100
- Current price:
- $40.17
- Market capitalization:
- $503.8M
- Revenue:
- $36.2M
- Net income:
- $31.5M
- Free cash flow:
- $2.9M
- Cash:
- $94.5M
- Total debt:
- $124.7M
- EPS:
- 1.53
- P/E ratio:
- 26.3x
- Financial score:
- 60/100
- Valuation score:
- 72/100
- Revenue score:
- 47/100
What stands out
- Reported year-over-year revenue growth is -0.3%.
- Free cash flow is $2.9M, showing positive cash generation.
- The balance sheet shows $94.5M of cash versus $124.7M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 72/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 60/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research XOMA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.